Abstract
Adrenomedullin (ADM) is a 52-amino acid peptide with structural homology to calcitonin generelated peptide (CGRP) initially isolated from human pheochromocytoma. ADM is synthesized and is secreted from many mammalian tissues, including the adrenal medulla, endothelial and vascular smooth muscle cells, as well as the myocardium and central nervous system. ADM has been implicated as a mediator of several diseases such as cardiovascular and renal disorders, sepsis, inflammation, diabetes and cancer. ADM is also expressed in a variety of tumors, including breast, endometrial and prostate cancer. ADM has been shown to be a mitogenic factor capable of stimulating growth of several cancer cell types. In addition, ADM is a survival factor for certain cancer cells and an indirect suppressor of the immune response. ADM plays an important role in environments subjected to low oxygen tension, which is a typical feature of solid tumors. Under these conditions, ADM is up regulated and acts as a potent angiogenic factor promoting neovascularization. The major focus of this review will be on the role of ADM in cancer, with emphasis on its utility in diagnostic and prognostic terms, along with its relevance as a therapeutic target.
Keywords: Adrenomedullin, tumor, progression, angiogenesis, hypoxia
Current Cancer Drug Targets
Title: Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Volume: 6 Issue: 7
Author(s): Misa Nakamura, Bo Han, Osamu Nunobiki and Kennichi Kakudo
Affiliation:
Keywords: Adrenomedullin, tumor, progression, angiogenesis, hypoxia
Abstract: Adrenomedullin (ADM) is a 52-amino acid peptide with structural homology to calcitonin generelated peptide (CGRP) initially isolated from human pheochromocytoma. ADM is synthesized and is secreted from many mammalian tissues, including the adrenal medulla, endothelial and vascular smooth muscle cells, as well as the myocardium and central nervous system. ADM has been implicated as a mediator of several diseases such as cardiovascular and renal disorders, sepsis, inflammation, diabetes and cancer. ADM is also expressed in a variety of tumors, including breast, endometrial and prostate cancer. ADM has been shown to be a mitogenic factor capable of stimulating growth of several cancer cell types. In addition, ADM is a survival factor for certain cancer cells and an indirect suppressor of the immune response. ADM plays an important role in environments subjected to low oxygen tension, which is a typical feature of solid tumors. Under these conditions, ADM is up regulated and acts as a potent angiogenic factor promoting neovascularization. The major focus of this review will be on the role of ADM in cancer, with emphasis on its utility in diagnostic and prognostic terms, along with its relevance as a therapeutic target.
Export Options
About this article
Cite this article as:
Nakamura Misa, Han Bo, Nunobiki Osamu and Kakudo Kennichi, Adrenomedullin: A Tumor Progression Factor via Angiogenic Control, Current Cancer Drug Targets 2006; 6 (7) . https://dx.doi.org/10.2174/156800906778742442
DOI https://dx.doi.org/10.2174/156800906778742442 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Epigenomic-Basis of Preemptive Medicine for Neurodevelopmental Disorders
Current Genomics The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism Further Vitamin D Analogs
Current Vascular Pharmacology Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Experience with Androgen Deprivation Therapy for Prostate Cancer in Japan and Future Perspectives
Current Cancer Drug Targets Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin
Current Drug Targets Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Star Graphs of Protein Sequences and Proteome Mass Spectra in Cancer Prediction
Current Proteomics Cellular and Physiological Effects of Arginine
Mini-Reviews in Medicinal Chemistry Targeting Mitogen-Activated Protein Kinase Phosphatase-1 (MKP-1): Structure-Based Design of MKP-1 Inhibitors and Upregulators
Current Medicinal Chemistry New Robotic Technologies in Cancer Colon Screening
Clinical Cancer Drugs Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
Current Genomics Transcription Factors: Molecular Targets for Prostate Cancer Intervention by Phytochemicals
Current Cancer Drug Targets Mitogenomics: Recognizing the Significance of Mitochondrial Genomic Variation for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Inflammation, Serotonin and Major Depression
Current Drug Targets